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Abstract ABCC6 belongs to the adenosine triphosphatebinding cassette (ABC) gene subfamily C. This protein family is involved in a large variety of physiological processes, such as signal transduction, protein secretion, drug and antibiotic resistance, and antigen presentation [Kool et al. (1999) 
ABCC6 in man: structure, function and physiological substrates
Human ABCC6, formerly called MRP6, belongs to the adenosine triphosphate (ATP)-binding cassette (ABC) gene subfamily C, together with ABCC1-13 [7, 25] . In man, ABCC6 consists of 31 exons spanning ∼73 kb genomic DNA. The ABCC6 mRNA is approximately 6 kb and has an open reading frame of 4.5 kb. The latter encodes a protein of 1503 aa. ABCC6 is composed of 17 transmembrane spanning domains and two evolutionary conserved intracellular nucleotide binding folds (NBFs). The NBFs contain conserved Walker A and B domains, and a C motif critical for ATP binding and transmembrane transporter functions [9, 21] . The putative protein structure is presented in Fig. 1 .
Two ABCC6 pseudogenes have been identified, which are, respectively, homologous to exon 1 through intron 4, and exon 1 through intron 9 [8, 14] .
The exact function and natural substrate(s) of ABCC6 are currently unknown. ABCC6 is highly homologous to ABCC1 (43% identity on amino acid level) [25] . For that reason, ABCC6 was classified as a multidrug resistanceassociated protein. However, subsequently, Kool et al. [25] and Belinsky et al. [4] showed that the role of ABCC6 in drug resistance is limited to low-level resistance of a number of compounds, like etoposide, teniposide, doxorubicin, and daunorubicin. In vitro experiments showed that ABCC6 actively transports the glutathione S-conjugates leukotriene C(4) and S-(2, 4-dinitrophenyl) glutathione, and the cyclopentapeptide BQ123 [4, 22, 32] .
ABCC6 is highly expressed in human liver and kidneys ( Fig. 2) [6, 25] . Low-expression levels of ABCC6 were detected in numerous other tissues, including skin, neural retina, and vessel walls [2, 6, 25] . Using several polyclonal antibodies, ABCC6 was localized to the basolateral side of human hepatocytes and to the basolateral membranes of the proximal kidney tubules. The latter suggests that ABCC6 transports intracellular biomolecules back into the blood [45] .
ABCC6 mutations cause pseudoxanthoma elasticum (PXE)

Pseudoxanthoma elasticum
The gene implicated in PXE was initially localized to a subchromosomal segment of chromosome 16 [28, 46, 50] , which contained both the ABCC1 and ABCC6 genes. Subsequently, several groups showed that loss of function mutations in ABCC6 were responsible for PXE [5, 28, 29] . PXE is primarily an autosomal recessive disorder of the connective tissue, affecting the skin, eye, and the cardio- Fig. 1 Point mutations in ABCC6 implicated in PXE. All missense and nonsense mutations described so far in the ABCC6 gene implicated in PXE. Deletions, insertions, etc. associated with PXE are given in Table 1 . Note the unequal distribution of mutations found, and the concentration of mutations in the functionally important NBF domains and the 8th intracellular loop The main sites of ABCC6 expression (liver and kidney) do not match the main sites of PXE pathology (skin, eye, and blood vessels). One possible explanation for these data is that PXE is a systemic disease caused by changes in blood composition that occur when the transport function of ABCC6 in liver and kidney is disturbed vascular system (Fig. 2) [11, 37, 41, 42] . Pseudodominance occurs apparently frequently, due to high carrier frequency and consanguinity [41] . Also, a number of heterozygote carriers manifest mild symptoms of the disease [1] . PXE is, so far, incurable and appears to be present in all of the world's populations, with an estimated prevalence of at least 1: 70,000 persons [9, 41] .
Histopathologically, progressive mineralization and fragmentation of elastic fibers in skin, Bruch's membrane in the retina, as well as vessel walls can be seen [11, 15, 37] . Mineralization of fragmented elastic fibers can be visualized using a Von Kossa stain [51] . The clinical expression of PXE is heterogeneous, with considerable variation in age of onset, progression, and severity, even within families [5, 20, 41] . Patients usually develop skin lesions and angioid streaks. Skin abnormalities frequently start at the side of the neck ( Fig. 3 ) and in flexural areas such as armpits, antecubital and popliteal fossae, the inguinal region, and the periumbilical area. Skin lesions are usually ivory to yellowish-colored, raised papules of 1-3 mm. The papules may have a linear or reticular arrangement and may coalesce into plaques or larger confluent areas. In a number of PXE cases, the skin becomes wrinkled, redundant, and hangs in folds [21, 37] . Ocular disease eventually develops in all patients with PXE. The usual sequence of developing eye abnormalities is peau d'orange, angioid streaks, peripapillary atrophy, white glial tissue formation, and finally, subretinal neovascularization (Fig. 3) . The latter results in disciform scarring of the macula which causes decreased visual acuity [21] . The most common cardiovascular complications in PXE are: diminished or absent peripheral vascular pulsations (in 25% of patients), early onset renovascular hypertension and echographic opacities due to calcification of arteries in kidneys, spleen, and pancreas (25%), arterial hypertension (22.5%), angina pectoris (19%), intermittent claudication (18%), and gastrointestinal hemorrhages (13%). In PXE patients, the compressibility of the carotid arterial wall was 44% higher than in control subjects, perhaps due to a higher amount of proteoglycans in the PXE vessel walls [9] . The PXE phenotype was recently extensively reviewed by Hu et al. [21] . Nonsense and missense mutations are given in Fig. 1 Mutations in ABCC6 cause pseudoxanthoma elasticum
Mutations in ABCC6 are implicated in pseudoxanthoma elasticum (PXE) [6, 27, 29, 44] . Currently, at least one ABCC6 mutation is found in 90% of our patients with a clinically well-characterized PXE phenotype [19] (unpublished results). So far, approximately 100 different mutations have been reported in ABCC6 (Fig. 1, Table 1 ) [9, 23, 35] .
The most important sequence changes are missense (55%) and nonsense (15%) mutations, as well as small deletions (15%). The remainder of pathogenic variants consists of splicing errors, larger deletions, and a number of insertions.
At least 30% of all mutations cause a frameshift and the introduction of a stopcodon, which leads to premature chain termination. Most pathogenic sequence changes replace evolutionary conserved residues [9, 20, 27] .
Mutations associated with PXE occur in, virtually, every exon of ABCC6. The vast majority of mutations occur in cytoplasmatic domains and the carboxy-terminal end of the ABCC6 protein. Only sporadically, pathogenic variants were found in extracellular and transmembrane domains. Mutations especially target the NBF1 and NBF2 domains, and the 8th intracellular loop [20] . The latter distribution strongly supports the critical role of NBFs in ATP-driven transport. In addition, this distribution suggests that the 8th intracellular loop is functionally important, perhaps for ABCC6 substrate recognition [9, 20, 27] .
Two ABCC6 mutations, R1141X and del(ex23_29), occur very frequently, probably due to founder effects and genetic drift. R1141X accounts for up to 30% of mutations found in European populations [9, 18] , but accounts for only 4% of the US PXE population. In contrast, ABCC6 del (ex23_29) is present in 28% of the US population [9, 27] , and in 4% of the European one. R1141X probably produces an instable ABCC6 mRNA which is rapidly degraded by nonsense mediated RNA decay [18, 29] .
Finally, R1141X may be associated with premature coronary artery disease [48] .
ABCC6 and PXE in man: expression, protein distribution, pathology
Currently, the mainstream hypothesis is that PXE is a systemic disorder, caused by ABCC6 defects in the liver and kidney (Fig. 2) [49] . However, the alternative hypothesis is that PXE is a local, peripheral defect, and that ABCC6 defects play a direct role at the sites of pathology [38] [39] [40] 43] . Obviously, these hypotheses are not mutually exclusive.
How does ABCC6 gene expression and protein localization in man relate to PXE pathogenesis? Reverse transcription polymerase chain reaction (RT-PCR), polymerase chain reaction Q-PCR, and immunohistochemistry studies all suggest that ABCC6 is highly expressed in the liver and kidney [6, 25, 45] . Interestingly though, neither organ is, apparently, the primary site of pathology in PXE. No liver pathology has been described in PXE. Kidney defects are apparently more common, because 25% of PXE patients get calcification of arteries in kidneys, spleen, and pancreas revealed by echographic opacities, resulting in renovascular hypertension [12, 17, 47] . However, even within the kidney, the sites of ABCC6 expression, and PXE pathology, apparently, do not match.
RT-PCR and immunohistochemistry with anti-ABCC6 polyclonal antibodies suggest that ABCC6 is lowly expressed or absent at the main sites of PXE pathogenesis: skin, vessel wall, and RPE/Bruch's membrane in the eye [6, 45] . The latter data strongly favor a systemic disease origin hypothesis [49] , although a pathogenic systemic-local interaction cannot be excluded. In a few tissues, like lungs, both ABCC6 expression and PXE pathogenesis are absent [6, 25] . [16] Abcc6 in mice: structure, function and physiological substrates
The mouse has been employed successfully as a model organism to study the function of several ABC transporters, such as ABCC1 [31, 52] , ABCC3 [53] , and ABCC7 (CFTR) [13] . The mouse genome contains homologues for at least 11 of the 13 human ABCC genes. Abcc6 is evolutionarily well conserved between mouse and man. The mouse Abcc6 is, with 1,498 amino acids, only four amino acids shorter than human ABCC6. The identity at the amino acid level is 78%. The predicted topology is similar to that of human ABCC6 with 17 transmembrane domains and two intracellular NBFs. In the mouse genome, Abcc6 and Abcc1 are physically separated, located, respectively, on chromosomes 7 and 16. The transport characteristics of mouse Abcc6 have not been studied yet. As Abcc6 knock out mice were recently generated, suitable tissues for transport studies are now available.
Targeted disruption of Abcc6 in the mouse: PXE-like signs
To clarify the function of Abcc6 and its relation with PXE, the Abcc6 gene was disrupted in the mouse by gene targeting. Two Abcc6 knock out mouse models (Abcc6 −/− ) were generated [16, 24] . The strategies used for disrupting Abcc6 were quite similar and consisted of deleting the coding sequence of the first NBF. This should render any remaining gene product dysfunctional, as NBF regions are crucial for the transport function of ABC proteins. In addition, mutations in this region in man cause PXE (Fig. 1) [20, 27] . In both Abcc6 −/− mouse models, the production of Abcc6 protein is apparently abolished, as judged from the absence of Abcc6 immunoreactivity in the liver (Fig. 4) [16, 24] .
The phenotype of the Abcc6 −/− mice was analyzed focusing on those tissues that are affected in PXE (skin, eye, and blood vessels). Necropsy of Abcc6 −/− mice revealed pathology specifically in all these tissues. Blood vessel pathology was most prominent in the mouse. In young Abcc6
−/− mice, calcification was observed in the wall of medium-sized arteries in the cortex of the kidney and in the capsule surrounding the sinuses of the vibrissae. It is currently not known why these vessel walls represent predilected sites of calcification in the Abcc6-deficient mouse. Calcification progresses with age and affects mice more than 12-15 months of age, also the aorta, coronary arteries, vena cava, as well as blood vessels in many of the tissues examined, such as muscle, tongue and adipose tissue. The calcium deposits are often found at or close to the elastic fibers in the vessel walls. In old Abcc6 −/− mice, also the eye and skin become involved, showing calcification in Bruch's membrane of the eye and in the dermis. In conclusion, Abcc6 −/− mice spontaneously develop a PXElike pathology, which confirms the crucial role of Abcc6 in the etiology of PXE.
Abcc6 and PXE in mice: expression, protein distribution, pathology
The phenotypic resemblance between PXE patients and Abcc6 −/− mice indicates that the Abcc6 −/− mouse is a useful tool to study the functional role of Abcc6 (as a transporter) in PXE pathophysiology. An important question in this respect is whether Abcc6 is present locally at the pathogenic sites. Several studies have examined the tissue distribution of Abcc6 mRNA and protein in the mouse. Significant levels of mRNA have been repeatedly found in liver, kidney and small intestine [33, 34, 36] . At the protein level, Abcc6 immunoreactivity is readily demonstrated at the basolateral membranes of hepatocytes and basal membranes of the proximal tubules in the kidney (Fig. 4 ) [16] . There are also reports of a more widespread distribution of messenger and protein in the mouse [3] . High sensitive RNAse protection assays [3] and RT-PCR [6, 34] have detected small amounts of Abcc6 transcripts in a variety of other tissues, including the sites of pathology. However, the biological significance of these low levels of mRNA remains questionable, especially because many of these messengers are Abcc6 splice variants harboring premature stopcodons [34] . At the protein level, a recent study using tissues from Abcc6 −/− mice as negative controls, failed to detect Abcc6 immunoreactivity at the pathogenic sites in skin, blood vessels and eye [16] . In summary, these expression studies did not support the local dysfunction of Abcc6 as the primary cause for PXE pathology. On the contrary, the data favor a systemic origin of PXE because the expression in liver, kidney, and small intestine put Abcc6 in a strategic position to control the blood values of its substrate. The nature of this substrate is currently not known. Analysis of the blood of Abcc6 −/− mice revealed no aberrant concentration of minerals, such as calcium. However, Abcc6 −/− mice do develop a reduction in plasma levels of high-density lipoprotein (HDL)-cholesterol, which suggests that Abcc6 may (also) be involved in lipid transport or metabolism.
Conclusions and perspectives
Five years ago, the discovery that PXE patients carry mutations in ABCC6 came as a surprise because a relation between this membrane transporter with PXE was not immediately apparent [6, 29] . Since then, this relation has been further strengthened, e.g., by the detection of ABCC6 mutations in up to 90% of the PXE patients and the PXElike phenotype in Abcc6 knock out mice [16, 24] . Currently, ABCC6 is considered to be the only disease gene causing PXE.
Despite this increased certainty that ABCC6 mutations cause PXE, the function of ABCC6 and its role in PXE remain largely unresolved. Fortunately, Abcc6 knock out mice are now available and the close resemblance in phenotype with PXE patients suggest that they will be valuable for analysis of the role of Abcc6 in PXE.
Several questions need to be addressed. First, an important issue still is whether PXE is a systemic or local disease. This can be initially addressed by studying Abcc6 expression and localization of the protein in the mouse, with Abcc6 −/− tissues as negative controls. However, it cannot be completely excluded that low and hardly detectable levels of Abcc6 may have physiological relevance. Therefore, functional studies are required for a more definitive answer. These studies may consist of reintroducing Abcc6 in a tissue-specific manner in the Abcc6 −/− mouse. The next urgent question is the identification of the substrate of ABCC6. Currently, hepatocytes are the most obvious cell type of choice for transport studies, because these cells express Abcc6 abundantly. Examination of the effect of Abcc6 deficiency on gene expression in the liver may suggest candidate substrates. In addition, suggestions for candidate substrates may come from analyzing the blood of PXE and normal persons. The first analysis of blood samples of the Abcc6 −/− mouse indicated that HDLcholesterol values change in Abcc6 −/− mice [16] . However, no significant changes in HDL-cholesterol have been observed so far in our PXE patients (unpublished results).
In case of a local disease, fibroblasts are the cell type of choice for studies to identify the substrate specificity of ABCC6. Indications for the substrate may be obtained by comparing physiology and gene expression of cultured fibroblasts from PXE patients and from healthy control persons. Possibly, toxicity assays can be developed using toxic agents such as saltpeter fertilizers, which upon contact cause PXE-like skin lesions [10] .
The final challenge will be to unravel PXE etiology and to prevent or even cure the disease. However, many aspects of PXE pathogenesis are still unknown. For example, in the eye of PXE patients, fundus signs, such as white punched out lesions, comet-like tails, and peau d'orange occur frequently. The histological and pathological correlate of these features is unknown. In tissues that develop a PXElike pathology in the Abcc6 −/− mouse, the sequence of events can be analyzed in detail and we can try to intervene experimentally. In addition, the Abcc6 −/− mouse models will enable us to test a variety of potential experimental therapies for PXE, ranging from dietary intervention to gene therapy.
